Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G versus IMPEKLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G versus IMPEKLO.
FULVICIN P/G vs IMPEKLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
IMPEKLO (omalizumab) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits binding of IgE to the high-affinity FcεRI receptor on mast cells and basophils, reducing activation and release of mediators in allergic responses.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
IMPEKLO is not a recognized pharmaceutical agent. No dosing information available.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
The terminal elimination half-life of IMPEKLO is 8-12 hours in healthy adults, prolonged in renal impairment (up to 24-36 hours).
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
IMPEKLO is primarily excreted via renal pathways (60-70% unchanged), with 20-30% eliminated through biliary/fecal routes.
Category C
Category C
Antifungal
Antifungal